AstraZeneca

Overview

AstraZeneca is a global pharmaceutical company with over 100,000 full-time employees. Its enterprise AI program is among the most developed in the industry, run by a 900-person unit led by Jorge Reis-Filho, Chief of AI for Science Innovation — a pathologist by training who retrained as a bioinformatician around 2000. The company holds 15 years of oncology translational data spanning 8 therapeutic modality categories, giving it a rare longitudinal clinical data asset.

AstraZeneca's AI strategy centers on insourcing domain-specific frontier foundation models fine-tuned on proprietary clinical trial data. The long-term target is early-fusion, single-patient representation — encoding all data modalities and time points into one vector per patient. The company filed its first AI biomarker FDA submission in 2023 and received breakthrough device designation in 2025. Its pathology foundation models now perform more than 30 tasks at superhuman accuracy. AstraZeneca's partnership ecosystem spans five categories: hyperscalers, frontier AI labs (including Anthropic), specialized AI companies, academics, and patient advocates.